RAPT Therapeutics Form 4 / Brian Russell Wong ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Wong Brian Russell

(Last)

(First)

(Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$12	11/13/2024		D⁽¹⁾			83,333	⁽¹⁾	10/29/2029	Common Stock	83,333	$0	0	D
Employee Stock Option (right to buy)	$1.57	11/13/2024		A⁽¹⁾		83,333		⁽¹⁾	10/29/2029	Common Stock	83,333	$0	83,333	D
Employee Stock Option (right to buy)	$44.66	11/13/2024		D⁽²⁾			60,000	⁽³⁾	01/29/2030	Common Stock	60,000	$0	0	D
Employee Stock Option (right to buy)	$1.57	11/13/2024		A⁽²⁾		60,000		⁽³⁾	01/29/2030	Common Stock	60,000	$0	60,000	D
Employee Stock Option (right to buy)	$19.53	11/13/2024		D⁽⁴⁾			150,000	⁽⁵⁾	01/27/2031	Common Stock	150,000	$0	0	D
Employee Stock Option (right to buy)	$1.57	11/13/2024		A⁽⁴⁾		150,000		⁽⁵⁾	01/27/2031	Common Stock	150,000	$0	150,000	D
Employee Stock Option (right to buy)	$19.86	11/13/2024		D⁽⁶⁾			300,000	⁽⁷⁾	01/27/2032	Common Stock	300,000	$0	0	D
Employee Stock Option (right to buy)	$1.57	11/13/2024		A⁽⁶⁾		300,000		⁽⁷⁾	01/27/2032	Common Stock	300,000	$0	300,000	D
Employee Stock Option (right to buy)	$29.05	11/13/2024		D⁽⁸⁾			250,000	⁽⁹⁾	01/30/2033	Common Stock	250,000	$0	0	D
Employee Stock Option (right to buy)	$1.57	11/13/2024		A⁽⁸⁾		250,000		⁽⁹⁾	01/30/2033	Common Stock	250,000	$0	250,000	D
Employee Stock Option (right to buy)	$24.75	11/13/2024		D⁽¹⁰⁾			275,000	⁽¹¹⁾	01/30/2034	Common Stock	275,000	$0	0	D
Employee Stock Option (right to buy)	$1.57	11/13/2024		A⁽¹⁰⁾		275,000		⁽¹¹⁾	01/30/2034	Common Stock	275,000	$0	275,000	D

Explanation of Responses:

1. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 30, 2019 and is fully vested.

2. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 30, 2020.

3. 1/48th of the shares subject to the option vested or shall shall vest on each monthly anniversary of the vesting start date of January 1, 2020.

4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 28, 2021.

5. 1/48th of the shares subject to the option vested or shall vest on each monthly anniversary of the vesting commencement date of January 1, 2021.

6. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 28, 2022.

7. 1/48th of the shares subject to the option vested or shall vest on each monthly anniversary of the vesting commencement date of January 1, 2022.

8. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 31, 2023.

9. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of January 1, 2023.

10. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 31, 2024.

11. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of January 1, 2024.

	/s/ Rodney Young, Attorney-in-Fact	11/15/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

RAPT Therapeutics (RAPT) Form 4RAPT Therapeutics / Brian Russell Wong ownership change